Aletheian Wealth Advisors LLC Reduces Stake in Eli Lilly and Company $LLY

Aletheian Wealth Advisors LLC reduced its stake in Eli Lilly and Company (NYSE:LLY) by 9.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,020 shares of the company’s stock after selling 101 shares during the quarter. Aletheian Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $795,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Peterson Wealth Advisors LLC grew its holdings in Eli Lilly and Company by 4.4% in the 2nd quarter. Peterson Wealth Advisors LLC now owns 839 shares of the company’s stock valued at $654,000 after buying an additional 35 shares in the last quarter. TruWealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 4.3% during the 2nd quarter. TruWealth Advisors LLC now owns 33,461 shares of the company’s stock worth $26,083,000 after purchasing an additional 1,379 shares during the period. RB Capital Management LLC grew its holdings in shares of Eli Lilly and Company by 6.8% during the 2nd quarter. RB Capital Management LLC now owns 4,504 shares of the company’s stock worth $3,511,000 after purchasing an additional 285 shares during the period. Arvest Investments Inc. grew its holdings in shares of Eli Lilly and Company by 18.4% during the 2nd quarter. Arvest Investments Inc. now owns 1,285 shares of the company’s stock worth $1,002,000 after purchasing an additional 200 shares during the period. Finally, Garde Capital Inc. grew its holdings in shares of Eli Lilly and Company by 20.6% during the 2nd quarter. Garde Capital Inc. now owns 1,604 shares of the company’s stock worth $1,250,000 after purchasing an additional 274 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $754.90 on Friday. The stock’s 50-day moving average price is $741.03 and its 200 day moving average price is $776.40. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $942.35. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market cap of $714.48 billion, a price-to-earnings ratio of 49.34, a PEG ratio of 1.05 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were given a $1.50 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 39.22%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on LLY shares. HSBC upgraded Eli Lilly and Company from a “reduce” rating to a “hold” rating and increased their price target for the stock from $675.00 to $700.00 in a report on Wednesday, August 27th. Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a report on Sunday, August 17th. Guggenheim lowered their price target on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Morgan Stanley reiterated an “overweight” rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Finally, DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $941.35.

Insider Buying and Selling

In related news, Director Jamere Jackson purchased 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director directly owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 over the last ninety days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.